Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Curr Pharm Des. 2022;28(22):1843-1853. doi: 10.2174/1381612828666220513125312.
Various anticancer drugs are effective therapeutic agents for cancer treatment; however, they cause severe toxicity in body organs. Cardiotoxicity is one of the most critical side effects of these drugs. Based on various findings, turmeric extract has positive effects on cardiac cells.
This study aims to evaluate how curcumin, as the main component of turmeric, may affect chemotherapy- induced cardiotoxicity.
A database search was performed up to April 2021 using "curcumin OR turmeric OR Curcuma longa" and "chemotherapy-induced cardiac disease", including their equivalents and similar terms. After screening the total articles obtained from the electronic databases, 25 relevant articles were included in this systematic review.
The studies demonstrate lower body weight and increased mortality rates due to doxorubicin administration. Besides, cancer therapeutic agents induced various morphological and biochemical abnormalities compared to the non-treated groups. Based on most of the obtained results, curcumin at nontoxic doses can protect the cardiac cells mainly through modulating antioxidant capacity, regulation of cell death, and antiinflammatory effects. Nevertheless, according to a minority of findings, curcumin increases the susceptibility of the rat cardiomyoblast cell line (H9C2) to apoptosis triggered by doxorubicin.
According to most nonclinical studies, curcumin could potentially have cardioprotective effects against chemotherapy-induced cardiotoxicity. However, based on limited, contradictory findings demonstrating the function of curcumin in potentiating doxorubicin-induced cardiotoxicity, well-designed studies are needed to evaluate the safety and effectiveness of treatment with new formulations of this compound during cancer therapy.
多种抗癌药物是癌症治疗的有效治疗药物；然而，它们会导致身体器官严重毒性。心脏毒性是这些药物最严重的副作用之一。基于各种发现，姜黄提取物对心脏细胞有积极作用。
本研究旨在评估姜黄素（姜黄的主要成分）如何影响化疗引起的心脏毒性。
对截至 2021 年 4 月的数据库进行了检索，使用“curcumin OR turmeric OR Curcuma longa”和“chemotherapy-induced cardiac disease”，包括其等效词和类似词。对从电子数据库中获得的所有文章进行筛选后，纳入了 25 篇相关文章进行系统评价。
研究表明，由于多柔比星的给药，体重下降和死亡率增加。此外，癌症治疗剂与未治疗组相比，诱导了各种形态和生化异常。根据大多数获得的结果，姜黄素在非毒性剂量下可以通过调节抗氧化能力、调节细胞死亡和抗炎作用来保护心脏细胞。然而，根据少数发现，姜黄素增加了大鼠心肌细胞系（H9C2）对多柔比星触发的细胞凋亡的敏感性。
根据大多数非临床研究，姜黄素可能对化疗引起的心脏毒性具有心脏保护作用。然而，基于少数发现表明姜黄素在增强多柔比星诱导的心脏毒性方面的作用存在矛盾，需要进行精心设计的研究来评估在癌症治疗期间使用这种化合物的新制剂治疗的安全性和有效性。
